Daclatasvir

Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

Product Specifications

CAS Number

[1009119-64-5]

Product Name Alternative

BMS-790052; EBP 883

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Daclatasvir.html

Purity

99.57

Solubility

DMSO : ≥ 40 mg/mL

Smiles

O=C([C@@H](NC(OC)=O)C(C)C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C5=CN=C([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)N5)C=C4

Molecular Formula

C40H50N8O6

Molecular Weight

738.88

Precautions

H302, H315, H319, H335

References & Citations

[1]Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465 (7294) :96-100.|[2]David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.|[3]Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58 (8) :4555-64.|[4]Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8 (1) :12469.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Ann Hepatol. Nov-Dec 2019;18 (6) :816-824.|Antimicrob Agents Chemother. 2013 Mar;57 (3) :1180-91.|Antimicrob Agents Chemother. 2014 Aug;58 (8) :4555-64.|Antimicrob Agents Chemother. 2014 Jun;58 (6) :3327-34. |Antimicrob Agents Chemother. 2015 May;59 (5) :2496-507. |Antivir Res. 2019 Nov;171:104612.|Antiviral Res. 2017 Dec:148:5-14.|Antiviral Res. 2017 Oct:146:191-200.|Antiviral Res. 2020 May;177:104734.|Biomed Pharmacother. 2019 Aug:116:108976.|Biomed Pharmacother. 2024 Sep 2:179:117325.|bioRxiv. 2020 May.|bioRxiv. 2025 Oct 9.|Cell Rep. 2021 Nov 23;37 (8) :110049.|College of Medicine/School of Medicine. Seoul National University. 2016 Aug.|Department of Analytical Chemistry. Charles University. 2019 Jun.|Drug Metab Dispos. 2019 Jul;47 (7) :768-778. |EMBO Rep. 2016 Jul;17 (7) :1013-28.|Eur J Med Chem. 2018 Jan 1:143:1053-1065.|Eur J Pharmacol. 2019 Jun 15:853:111-120.|Eur J Pharmacol. 2020 Sep 15;883:173323.|Faculty of Pharmacy in Hradec Králové. Department of Pharmacology and Toxicology. Charles University 2019 Apr.|Front Pharmacol. 2016 Dec 21:7:490.|Front Pharmacol. 2018 Dec 19:9:1438.|Hepatol Commun. 2017 Jul 13;1 (6) :550-563.|Hepatology. 2019 May;69 (5) :1861-1872. |Int J Antimicrob Agents. 2015 Oct;46 (4) :381-8. |Int J Radiat Oncol Biol Phys. 2016 Nov 15;96 (4) :867-876. |J Gastroenterol. 2019 May;54 (5) :449-458. |J Hum Genet. 2020 Jan;65 (2) :143-153.|J Med Chem. 2020 Jun 11;63 (11) :5972-5989.|J Med Virol. 2023 Dec;95 (12) :e29290.|J Virol. 2014 May;88 (10) :5578-94. |Oncotarget. 2017 Dec 21;9 (5) :5627-5640.|Open Virol J. 2014 Mar 7;8:1-8.|Pharmaceuticals (Basel) . 2022 Feb 18;15 (2) :242.|PLoS One. 2015 Aug 11;10 (8) :e0134707. |PLoS One. 2016 Apr 22;11 (4) :e0152036. |PLoS One. 2016 Jul 21;11 (7) :e0159511.|PLoS Pathog. 2017 May 11;13 (5) :e1006374. |PLoS Pathog. 2018 Sep 18;14 (9) :e1007284. |Sci Rep. 2018 Jun 6;8 (1) :8676. |Transpl Infect Dis. 2018 Feb;20 (1) .|University of Glasgow. 2024 Mar.|Virus Res. 2017 May 2:235:37-48.|Viruses. 2018 Aug 28;10 (9) . pii: E462.|EMBO Mol Med. 2024 Apr;16 (4) :870-884.